IDRA-21

CAS No. 22503-72-6

IDRA-21( —— )

Catalog No. M21086 CAS No. 22503-72-6

IDRA-21 is a positive AMPA receptor modulator.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
25MG 35 Get Quote
50MG 58 Get Quote
100MG 88 Get Quote
200MG 140 Get Quote
500MG 236 Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    IDRA-21
  • Note
    Research use only, not for human use.
  • Brief Description
    IDRA-21 is a positive AMPA receptor modulator.
  • Description
    IDRA-21 is a positive AMPA receptor modulator.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Neuroscience
  • Target
    GluR
  • Recptor
    AMPA
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    22503-72-6
  • Formula Weight
    232.68
  • Molecular Formula
    C8H9ClN2O2S
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 250 mg/mL (1074.39 mM)
  • SMILES
    CC1Nc2ccc(Cl)cc2S(=O)(=O)N1
  • Chemical Name
    7-Chloro-3-methyl-3-4-dihydro-2H-124 benzothiadiazine SS-dioxide

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Buccafusco J J Weiser T Winter K et al. The effects of IDRA 21 a positive modulator of the AMPA receptor on delayed matching performance by young and aged rhesus monkeys[J]. Neuropharmacology 2004 46(1):10-22.
molnova catalog
related products
  • SBC-110736

    SBC-110736 is a proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor.

  • Basimglurant

    Basimglurant is a potent, selective and orally available modulator of mGlu5 negative allosteric(Kd of 1.1 nM). In competition binding experiments on human recombinant mGlu5, Basimglurant (RG7090) fully displaces [3H]-MPEP with a Ki of 35.6 nM and [3H]-ABP688 with a Ki of 1.4 nM. In HEK293 cells stably expressing human mGlu5, Basimglurant (RG7090) inhibits quisqualate induced Ca2+ mobilization with an IC50 of 7.0 nM and [3H]-inositolphosphate accumulation (IC50 of 5.9 nM).

  • KM02894

    KM02894 is a glutamate release inhibitor. Cancer cells release high levels of glutamate that can disrupt normal bone turnover, which can lead to cancer-induced bone pain.KM02894 may be used in the study of tumor-related diseases.